Chemotherapy of advanced breast cancer

Research output: Contribution to journalArticle

Abstract

The treatment of clinically overt metastatic breast cancer, despite several treatment modalities (biological response modifiers, megatherapy with autologous bone marrow transplantation, growth factors, new agents, etc.) is in a static phase. In the decision-making one has to consider the patient's age, her menstrual state, the metastatic site, previous adjuvant and/or postoperative treatment modalities. Roughly there are two treatment forms, the hormonal and the cytostatic ones. Endocrine therapy should be given as follows: 1. only for low risk group, 2. gestagen or antiestrogen therapy is the choice for the first step, 3. if there is a progression in 3 months, the hormonal treatment should be changed to cytostatic combination, 4. if there is a progression beyond 3 months further hormonal therapy can be considered. The efficacy of endocrine therapy is 30%. In patients with advanced breast cancer chemotherapy provides a response rate of 30 to 60%, however total survival of the patients does not improve substantially. Doxorubicin containing regimens are more effective, however no response in total survival can be obtained. New plant alkaloids and altered treatment forms will probably influence survival. Taking all these into consideration one has to decide on the quality of life of the breast cancer patients.

Original languageEnglish
Pages (from-to)185-193
Number of pages9
JournalActa Medica Hungarica
Volume50
Issue number3-4
Publication statusPublished - 1994

Fingerprint

Breast Neoplasms
Drug Therapy
Therapeutics
Cytostatic Agents
Survival
Estrogen Receptor Modulators
Autologous Transplantation
Immunologic Factors
Progestins
Bone Marrow Transplantation
Alkaloids
Doxorubicin
Intercellular Signaling Peptides and Proteins
Decision Making
Quality of Life

Keywords

  • advanced breast cancer
  • chemotherapy
  • decision-making
  • hormonal treatment
  • quality of life

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chemotherapy of advanced breast cancer. / Szántó, J.

In: Acta Medica Hungarica, Vol. 50, No. 3-4, 1994, p. 185-193.

Research output: Contribution to journalArticle

Szántó, J. / Chemotherapy of advanced breast cancer. In: Acta Medica Hungarica. 1994 ; Vol. 50, No. 3-4. pp. 185-193.
@article{f924e503b21c47e691affd249777ad0c,
title = "Chemotherapy of advanced breast cancer",
abstract = "The treatment of clinically overt metastatic breast cancer, despite several treatment modalities (biological response modifiers, megatherapy with autologous bone marrow transplantation, growth factors, new agents, etc.) is in a static phase. In the decision-making one has to consider the patient's age, her menstrual state, the metastatic site, previous adjuvant and/or postoperative treatment modalities. Roughly there are two treatment forms, the hormonal and the cytostatic ones. Endocrine therapy should be given as follows: 1. only for low risk group, 2. gestagen or antiestrogen therapy is the choice for the first step, 3. if there is a progression in 3 months, the hormonal treatment should be changed to cytostatic combination, 4. if there is a progression beyond 3 months further hormonal therapy can be considered. The efficacy of endocrine therapy is 30{\%}. In patients with advanced breast cancer chemotherapy provides a response rate of 30 to 60{\%}, however total survival of the patients does not improve substantially. Doxorubicin containing regimens are more effective, however no response in total survival can be obtained. New plant alkaloids and altered treatment forms will probably influence survival. Taking all these into consideration one has to decide on the quality of life of the breast cancer patients.",
keywords = "advanced breast cancer, chemotherapy, decision-making, hormonal treatment, quality of life",
author = "J. Sz{\'a}nt{\'o}",
year = "1994",
language = "English",
volume = "50",
pages = "185--193",
journal = "Acta Medica Hungarica",
issn = "0236-5286",
publisher = "Akademiai Kiado",
number = "3-4",

}

TY - JOUR

T1 - Chemotherapy of advanced breast cancer

AU - Szántó, J.

PY - 1994

Y1 - 1994

N2 - The treatment of clinically overt metastatic breast cancer, despite several treatment modalities (biological response modifiers, megatherapy with autologous bone marrow transplantation, growth factors, new agents, etc.) is in a static phase. In the decision-making one has to consider the patient's age, her menstrual state, the metastatic site, previous adjuvant and/or postoperative treatment modalities. Roughly there are two treatment forms, the hormonal and the cytostatic ones. Endocrine therapy should be given as follows: 1. only for low risk group, 2. gestagen or antiestrogen therapy is the choice for the first step, 3. if there is a progression in 3 months, the hormonal treatment should be changed to cytostatic combination, 4. if there is a progression beyond 3 months further hormonal therapy can be considered. The efficacy of endocrine therapy is 30%. In patients with advanced breast cancer chemotherapy provides a response rate of 30 to 60%, however total survival of the patients does not improve substantially. Doxorubicin containing regimens are more effective, however no response in total survival can be obtained. New plant alkaloids and altered treatment forms will probably influence survival. Taking all these into consideration one has to decide on the quality of life of the breast cancer patients.

AB - The treatment of clinically overt metastatic breast cancer, despite several treatment modalities (biological response modifiers, megatherapy with autologous bone marrow transplantation, growth factors, new agents, etc.) is in a static phase. In the decision-making one has to consider the patient's age, her menstrual state, the metastatic site, previous adjuvant and/or postoperative treatment modalities. Roughly there are two treatment forms, the hormonal and the cytostatic ones. Endocrine therapy should be given as follows: 1. only for low risk group, 2. gestagen or antiestrogen therapy is the choice for the first step, 3. if there is a progression in 3 months, the hormonal treatment should be changed to cytostatic combination, 4. if there is a progression beyond 3 months further hormonal therapy can be considered. The efficacy of endocrine therapy is 30%. In patients with advanced breast cancer chemotherapy provides a response rate of 30 to 60%, however total survival of the patients does not improve substantially. Doxorubicin containing regimens are more effective, however no response in total survival can be obtained. New plant alkaloids and altered treatment forms will probably influence survival. Taking all these into consideration one has to decide on the quality of life of the breast cancer patients.

KW - advanced breast cancer

KW - chemotherapy

KW - decision-making

KW - hormonal treatment

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=0028581820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028581820&partnerID=8YFLogxK

M3 - Article

C2 - 8587832

AN - SCOPUS:0028581820

VL - 50

SP - 185

EP - 193

JO - Acta Medica Hungarica

JF - Acta Medica Hungarica

SN - 0236-5286

IS - 3-4

ER -